Allergy Testing Access Act of 2021

Allergy Testing Access Act of 2021

This bill requires equal coverage of two types of allergy tests under Medicaid and Medicare.

Specifically, in vitro specific IgE tests (blood tests) and percutaneous tests (skin tests) must be treated equally with respect to (1) medical necessity or other coverage requirements, (2) frequency limits, and (3) allergen unit limits.

Bill 117 HR 4114, also known as the Allergy Testing Access Act of 2021, aims to improve access to allergy testing for individuals in the United States. The bill was introduced in the House of Representatives on March 1, 2021, by Representative Raul Ruiz of California.

The main purpose of the bill is to address the growing issue of limited access to allergy testing, which can be crucial for individuals with severe allergies. The bill seeks to increase access to allergy testing by allowing pharmacists to administer certain types of allergy tests, such as skin prick tests and patch tests, under the supervision of a physician.

Additionally, the bill aims to streamline the process for obtaining allergy testing by allowing individuals to receive testing without a prior diagnosis from a physician. This would make it easier for individuals to determine if they have allergies and seek appropriate treatment. Overall, the Allergy Testing Access Act of 2021 is designed to improve access to allergy testing for individuals in the United States, ultimately leading to better diagnosis and treatment of allergies. The bill is currently in the early stages of the legislative process and has not yet been voted on by the House of Representatives.